Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.0K
Clinical Trials01:16

Clinical Trials

9.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.4K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

218
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
218
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

932
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
932
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

574
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
574

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the Clinical Effectiveness and Cost-Effectiveness of Tirzepatide for Type 2 Diabetes in Canada Using Bayesian Transportability Analysis.

Value in health regional issues·2026
Same author

Clinical trial priorities, adaptive strategies, and equitable partnerships for the Bundibugyo Ebola outbreak.

The Lancet. Infectious diseases·2026
Same author

Anchoring convenience survey samples to a baseline census for vaccine coverage monitoring in global health.

Vaccine·2026
Same author

Ebola outbreak caused by Bundibugyo virus: challenges and priorities for epidemic preparedness and response.

Lancet (London, England)·2026
Same author

Logistical Challenges in Platform Randomized Trials - Operational Realities That Curb the Promise of Efficiency.

Clinical epidemiology·2026
Same author

Platform Trial Barriers-Why We Are Returning to Old Ways.

JAMA network open·2026

Related Experiment Video

Updated: Nov 5, 2025

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.0K

Moving forward in clinical research with master protocols.

Jay J H Park1, Louis Dron2, Edward J Mills2

  • 1Experimental Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Contemporary Clinical Trials
|May 17, 2021
PubMed
Summary
This summary is machine-generated.

Billions invested in COVID-19 research yielded poor returns for therapeutics, highlighting clinical trial inefficiencies. Structural changes are crucial for future pandemic preparedness and effective therapeutic development.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

17.6K
Measuring and Manipulating Functionally Specific Neural Pathways in the Human Motor System with Transcranial Magnetic Stimulation
09:52

Measuring and Manipulating Functionally Specific Neural Pathways in the Human Motor System with Transcranial Magnetic Stimulation

Published on: February 23, 2020

9.4K

Related Experiment Videos

Last Updated: Nov 5, 2025

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.0K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

17.6K
Measuring and Manipulating Functionally Specific Neural Pathways in the Human Motor System with Transcranial Magnetic Stimulation
09:52

Measuring and Manipulating Functionally Specific Neural Pathways in the Human Motor System with Transcranial Magnetic Stimulation

Published on: February 23, 2020

9.4K

Area of Science:

  • Medical Research
  • Clinical Trials
  • Epidemiology

Background:

  • The COVID-19 pandemic spurred unprecedented research and development (R&D) investment.
  • Significant R&D funding has been directed towards novel coronavirus disease 2019 (COVID-19) therapeutics.
  • The scientific community's response has faced challenges in delivering effective therapeutic solutions.

Purpose of the Study:

  • To analyze the return on investment (ROI) of COVID-19 therapeutic research.
  • To identify weaknesses and inefficiencies within the existing clinical trial enterprise.
  • To advocate for structural reforms in clinical trial research programs.

Main Methods:

  • Review of R&D funding allocation for COVID-19 therapeutics.
  • Analysis of clinical trial outcomes and success rates for COVID-19 treatments.
  • Comparative assessment of the clinical trial enterprise's response to the pandemic.

Main Results:

  • Despite substantial investment, therapeutic research for COVID-19 has shown a poor ROI.
  • The COVID-19 pandemic exposed significant structural weaknesses in clinical trial operations.
  • Existing research programs demonstrated inefficiencies in adapting to urgent global health needs.

Conclusions:

  • The current clinical trial system requires fundamental structural changes to improve efficiency and ROI.
  • Lessons learned from the COVID-19 pandemic necessitate reforms in research programs for future public health crises.
  • Implementing structural changes is vital for optimizing therapeutic development and pandemic response.